Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2-negative breast cancer patients in Israel: A registry analysis.
Bar-Sela G, Samih Y, Yerushalmi R, Leviov M, Efrat Ben-Baruch N, Kuchuk I, Tokar M, Peretz-Yablonski T, Sonnenblick A, Soussan-Gutman L, Bareket-Samish A, Fried G, Paluch-Shimon S, Kaufman B, Hammerman A, Liebermann N, Stemmer SM. Bar-Sela G, et al. Among authors: kuchuk i. Breast J. 2020 Oct;26(10):2096-2098. doi: 10.1111/tbj.13870. Epub 2020 May 18. Breast J. 2020. PMID: 32419268 No abstract available.
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Reinhorn D, Kuchuk I, Shochat T, Nisenbaum B, Sulkes A, Hendler D, Rotem O, Tsoref D, Olitzky O, Goldvaser H, Sarfaty M, Neiman V, Prus J, Gottfried M, Yust-Katz S, Yerushalmi R. Reinhorn D, et al. Among authors: kuchuk i. Breast Cancer Res Treat. 2021 Jul;188(2):379-387. doi: 10.1007/s10549-021-06198-4. Epub 2021 Mar 27. Breast Cancer Res Treat. 2021. PMID: 33772709
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP. Sella T, et al. Among authors: kuchuk i. Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22. Breast. 2018. PMID: 29800932
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. Addison CL, et al. Among authors: kuchuk i. Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18. Breast Cancer Res Treat. 2014. PMID: 24638849 Free PMC article. Clinical Trial.
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M. Jacobs C, et al. Among authors: kuchuk i. Breast Cancer Res Treat. 2016 Jan;155(1):77-84. doi: 10.1007/s10549-015-3646-2. Epub 2015 Dec 7. Breast Cancer Res Treat. 2016. PMID: 26643085 Clinical Trial.
37 results